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Abstract
Bordetella pertussis employs numerous strategies to evade the immune system, including the ability to resist killing via
complement. Previously we have shown that B. pertussis binds a complement regulatory protein, C1 esterase inhibitor
(C1inh) to its surface in a Bvg-regulated manner (i.e. during its virulence phase), but the B. pertussis factor was not identified.
Here we set out to identify the B. pertussis C1inh-binding factor. Using a serum overlay assay, we found that this factor
migrates at approximately 100 kDa on an SDS-PAGE gel. To identify this factor, we isolated proteins of approximately
100 kDa from wild type strain BP338 and from BP347, an isogenic Bvg mutant that does not bind C1inh. Using mass
spectrometry and bioinformatics, we identified the autotransporter protein Vag8 as the putative C1inh binding protein. To
prove that Vag8 binds C1inh, vag8 was disrupted in two different B. pertussis strains, namely BP338 and 18–323, and the
mutants were tested for their ability to bind C1inh in a surface-binding assay. Neither mutant strain was capable of binding
C1inh, whereas a complemented strain successfully bound C1inh. In addition, the passenger domain of Vag8 was expressed
and purified as a histidine-tagged fusion protein and tested for C1inh-binding in an ELISA assay. Whereas the purified Vag8
passenger bound C1inh, the passenger domain of BrkA (a related autotransporter protein) failed to do so. Finally, serum
assays were conducted to compare wild type and vag8 mutants. We determined that vag8 mutants from both strains were
more susceptible to killing compared to their isogenic wild type counterparts. In conclusion, we have discovered a novel
role for the previously uncharacterized protein Vag8 in the immune evasion of B. pertussis. Vag8 binds C1inh to the surface
of the bacterium and confers serum resistance.
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Introduction
Complement is a critical and multifaceted host defense system
comprised of a series of proteins—many of which are zymogens—
found largely in plasma [1] but also on respiratory mucosal
surfaces [2,3]. Three activation pathways of complement are
known today, designated the classical, lectin, and alternative
pathway. Following activation, complement components of all
three pathways act in a defined cascade to effect immune
clearance of microorganisms either directly by assembly of
membrane attack complexes, or indirectly by opsonization and
release of peptide mediators of inflammation which promote the
attraction of and recognition by various immune cells [1]. To
protect the host from the effector functions of complement and
prevent rapid consumption of complement components in
response to trivial stimuli, all three activation pathways of
complement are tightly regulated at different stages by a number
of complement regulatory proteins [4]. Bordetella pertussis, the
causative agent of whooping cough, has been shown to express a
variety of virulence-associated factors that in concert enable the
bacteria to colonize the mucosa of the upper respiratory tract in
humans. Expression of most virulence-associated factors in B.
pertussis is positively regulated by the BvgAS two component
system [5,6]. Apart from adherence of the bacteria to the ciliated
respiratory epithelium, many of these factors help the bacteria to
evade or modulate host immune defenses [7,8]. One of the
immune defenses to overcome is complement.
There is a basic necessity for B. pertussis to prevent complement
activation because the B. pertussis endotoxin lacks a repetitive O
polysaccharide [9] rendering the bacteria particularly vulnerable
to direct, complement-mediated bacterial lysis—unlike many other
Gram-negative bacteria including other Bordetella species where
endotoxin can act as a protective shield [10]. Indeed, B. pertussis is
relatively resistant to killing by complement [11]. We have
previously shown that the B. pertussis autotransporter protein BrkA
mediates resistance to the classical complement pathway [11] and
although this happens at a very early stage in the pathway [12],
the underlying molecular mechanism remains elusive. Interesting-
ly, B. pertussis expresses other factors in its virulence phase that can
interact with complement components or its regulators, either
directly or indirectly. Filamentous hemagglutinin (FHA) has been
shown to bind a complement regulator called C4-binding protein
(C4BP) [13,14], however how this affects serum resistance is not
known since B. pertussis mutants deficient in FHA expression
exhibit a level of complement resistance that is not significantly
different compared to their parental wild type strain [15]. We have
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20585recently demonstrated that B. pertussis is able to recruit another
complement regulatory protein of humans, C1 esterase inhibitor
(C1inh). This phenotype is associated with resistance to comple-
ment-mediated killing but requires neither the expression of BrkA
nor FHA [16,17]. With the present study we set out to identify the
B. pertussis factor that is responsible for the binding of human
C1inh to the bacterial surface, hence also crucial for serum
resistance. This factor was found to be the autotransporter protein
Vag8.
Results
Identification of the B. pertussis factor that mediates
recruitment of human C1-esterase inhibitor
We have previously shown that B. pertussis is capable of binding
human C1inh to its surface and that this is dependent on signal
transduction by the BvgAS two-component system, the master
virulence regulatory system of Bordetella species. Furthermore, the
ability of B. pertussis to bind human C1inh was found to be
independent of the Bvg-activated serum resistance protein BrkA
[16]. In the present study we aimed to identify the bacterial ligand
that interacts with human C1inh. We first tested a variety of well-
characterized B. pertussis mutants with defects in BvgAS-activated
genes using the C1inh binding assay that we described previously
[16]. These mutants included: BBC9BrkA (a derivative of wild
type W28) that does not express pertactin and BrkA [11,18]; SK34
(a derivative of wild type 18–323) that harbors a TnphoA insertion
in the tcfA locus [19]; BP338 (Tohama I)-derived Tn5lac mutants
BPM3171 and BPM1809 which fail to secrete pertussis toxin [20]
and lack the expression of dermonecrotic toxin [21], respectively;
as well as BP338 (Tohama I)-derived mutants BP348 and BP353
which harbor Tn5 insertions in cyaA (adenylate cyclase toxin) and
fimC (fimbria), respectively. The latter strain also does not express
filamentous haemagglutinin (FHA) due to a polar effect of the
transposon insertion [22,23]. Wild type BP338 and the isogenic
BvgS mutant BP347 (bvgS::Tn5) [22,23] were used as positive and
negative controls, respectively. We found that with the exception
of the BvgS mutant BP347, none of the B. pertussis mutants tested
here was visibly compromised in C1inh binding (data not shown).
Using microarray-based transcriptional profiling of Bvg
+ and
Bvg
2 phase-locked mutants, Cummings et al. [5] revealed that
155 genes are Bvg-activated in B. pertussis Tohama I-derived
strains. To narrow down the list of candidate B. pertussis factors
potentially involved in the recruitment of C1inh, we employed a
modification of a so-called Far-Western or gel-overlay strategy
described elsewhere [24], in combination with mass spectrometry.
This technique has been used to study protein-protein interactions
[24] and it enabled us to determine the approximate molecular
mass of the factor expressed by B. pertussis that mediates
recruitment of C1inh. In brief, whole cell lysates of B. pertussis
strains BP338 and BP347 were subjected to SDS-PAGE.
Separated proteins were blotted onto a PVDF membrane and
subsequently renatured. Membranes were then overlaid with 1%
normal human serum, and human C1inh interacting with any B.
pertussis factor on the PVDF membrane was detected by standard
immunoblot analysis. Using this approach, we found human
C1inh to interact with a B. pertussis factor migrating at
approximately 95 to 100 kDa that was expressed in wild type
BP338 but absent in BvgS mutant BP347 (Fig. 1). To validate that
the bacterial factor in question is indeed subject to BvgAS
regulation, we cultivated wild type BP338 in the absence or
presence of 50 mM MgSO4 (which turns off the Bvg system) and
employed the Far-Western strategy described above. As shown in
figure 1, the B. pertussis factor capable of binding human C1inh
was absent when the bacteria were grown under BvgAS-
modulating conditions.
To identify BvgAS-regulated bacterial factors migrating at ca.
95 to 100 kDa on SDS-PAGE gels, crude membrane enrichments
of wild type strain BP338 (grown under Bvg-activating conditions)
and BvgS mutant BP347 were separated by SDS-PAGE and the
polyacrylamide gel stained with Coomassie blue. A visible protein
band migrating at the appropriate molecular weight and present in
BP338 but absent in BP347 was excised out of the protein gel.
Corresponding regions from the lane containing membrane
enrichments of BvgS mutant BP347 were similarly excised.
Trypsin-digested peptides of the gel samples from both strains
were subjected to MS/MS analysis, and a search of the obtained
data against the protein sequence database MSBD was performed
using Mascot. Using this approach, we identified five significant
matches of proteins that were present in membrane enrichments of
BP338, but were not detected in BvgS mutant BP347; namely the
gene product of virulence-activated gene 8 (Vag8), Bvg-interme-
diate phase protein A (BipA), pertactin, a pyruvate dehydrogenase
E1 component and DNA gyrase subunit B (Table 1).
Because the latter two hits are components of essential cytosolic
enzymes that were likely present in BvgS mutant BP347 but which
remained undetected, and since the B. pertussis pertactin-BrkA
double mutant BBC9BrkA was found to be capable of binding
C1inh, we decided to focus on Vag8 and BipA. bipA and vag8 were
disrupted using suicide vectors pTEN34 and pEG7-vag8,
respectively and hemolytic B. pertussis mutants with genomic
insertions of pTEN34 or pEG7-vag8 were isolated and designated
as BP338BipA
2 or BP338Vag8
2. Correct genomic integration of
the suicide vectors was validated by PCR of the genomic insertion
site using vector-specific primers in combination with a bipA or a
vag8 promoter-specific primer that could not hybridize to pTEN34
or pEG7-vag8, respectively. PCR products of the expected sizes
were found when using genomic DNA of both mutants as
templates, whereas no product was detected with genomic DNA of
wild type BP338 that served as the negative control. The vag8
results are shown in Figure 2(A and B). The PCR products
generated from genomic DNA of mutants BP338BipA
2 and
Figure 1. Far-Western analysis showing interaction of C1inh
from normal human serum with an unknown B. pertussis factor
migrating at ca. 90 to 100 kDa. B. pertussis strain BP338 (wild type)
and its isogenic mutant BP347 (bvgS::Tn5) were grown without (2)o r
with (+) Bvg-modulating agent MgSO4 (50 mM) prior to performing the
Far-Western assay using normal human serum as the probe, followed
by detection using anti-C1inh antibody.
doi:10.1371/journal.pone.0020585.g001
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2 were sequenced and found to encode the expected
genomic insertion sites.
Following verification of the mutation in BP338BipA
2 and
BP338Vag8
2, the two B. pertussis mutants were then assayed for
their ability to recruit human C1inh from human serum [16] and
to bind to C1inh by use of the Far-Western approach described
above. Wild type strain BP338 and BvgS mutant BP347 served as
positive and negative controls, respectively. Whereas B. pertussis
mutant BP338BipA
2 was found to be capable of binding human
C1inh using both the surface-binding and the Far Western overlay
assays, BP338Vag8
2 was not (Fig. 3A and B). The lack of C1inh
binding was not due to phase variation of the Bvg system as
demonstrated by the expression of the Bvg-activated BrkA protein
(Fig. 3C), and by hemolysis which is a function of the Bvg-
activated adenylate cyclase toxin. Furthermore, it is unlikely that
the lack of C1inh binding was due to a polar effect of the insertion
mutation as there are no genes in the same orientation
immediately downstream of vag8, and the gene immediately
following vag8 is in the opposite orientation (Fig. 2A). In any event,
to reproduce these findings, independent Vag8 mutants were
generated again in BP338 and in a streptomycin-resistant
derivative of a different B. pertussis strain called 18–323. All of
the Vag8 mutants expressed BrkA and were hemolytic, but were
unable to bind C1inh. These results strongly implicate Vag8 as the
C1inh-binding factor. Finally, we complemented one of the Vag8
mutants originated from B. pertussis BP338 with pVag8, a plasmid
that replicates in bordetellae and encodes a full-length open
reading frame (ORF) of vag8 driven by promoter Pcpn10. In parallel,
we introduced an empty vector control (pBBR1MCS2) or pBrkA
(a similar plasmid encoding brkA instead of vag8) into this Vag8
mutant via conjugation. As shown in Fig. 3D, we were able to
partially restore the ability to bind C1inh in the Vag8 mutant
complemented with the plasmid that encodes a full-length vag8
ORF, whereas no C1inh could be observed in the conjugants
harboring the empty vector control or pBrkA.
Vag8 is an autotransporter protein [25]. As is typical of
autotransporter proteins, it has a surface-exposed passenger
domain that provides the effector function, and a translocator
domain that is involved in secretion and anchoring of the Vag8
passenger to the bacterial surface (Fig. 2C). To further validate
that Vag8 binds C1inh, the passenger domain of Vag8 comprised
of residues Val
40 to Leu
610 was fused to a histidine tag and purified
using nickel chromatography. An ELISA was used to examine
whether the purified Vag8 passenger is capable of directly binding
C1inh. Briefly, Immuno 96 MicroWell MaxiSorp
TM plates were
coated with different concentrations of the purified Vag8
passenger domain, and after washing and then blocking non-
specific binding, the plates were probed with either purified C1inh
or human serum. Bound C1inh was detected using anti-C1inh
antiserum. Results using this assay confirm direct binding of the
Vag8 passenger domain to purified C1inh (Fig. 4A) or C1inh from
human serum (Fig. 4B) in a dose-dependent manner. In contrast,
the similar-sized (73-kDa) BrkA passenger domain [26] which
shares 27% identity to Vag8 (residues 205–604) failed to bind
C1inh. Similar observations were made using the Far-Western
approach described above (data not shown). No signal was
detected when we performed the ELISA on wells that were coated
with 5 mg/ml of the purified Vag8 passenger domain but not
Table 1. Genes encoding the proteins that were identified by tandem mass spectrometry.
Gene name Gene product Probability Based Mowse Score
BP338 BP347
BP2315 vag8 autotransporter Vag8 2011 not detected
BP2014 acnA Putative aconitate hydratase 1265 1251
BP1112 bipA putative OM ligand binding protein (BipA) 1185 not detected
BP0197 gcvP glycine cleavage system P protein not detected 238
BP2497 putative zinc protease 781 202
BP0460 topB DNA topoisomerase iii 346 458
BP0869 pepN aminopeptidase N 240 621
BP0993 aceE pyruvate dehydrogenase E1 component 234 not detected
BP1836 alaS, lovB alanyl-tRNA synthetase 219 662
BP0489 gyrB DNA gyrase subunit B 116 not detected
BP2573 pheT phenylalanyl-tRNA synthetase beta chain PheT 76 527
BP0944 gyrA DNA gyrase subunit A 67 273
BP2044 leucyl-tRNA synthetase 58 565
BP3467 putative exported protein 56 129
BP1054 prn pertactin 54 not detected
BP1549 dnaX DNA polymerase III subunit Tau not detected 168
BP1566 mutS DNA mismatch repair protein mutS not detected 143
BP2184 rpoD RNA polymerase sigma factor not detected 130
BP1198 clpB, htpM protease ClpB, ATPase subunit not detected 67
BP1417 glnD [Protein-PII] uridylyltransferase not detected 66
(MS/MS) analysis and ions search against protein sequence database MSDS using Mascott. All significant hits (P,0.05) with individual ions scores .50 are listed, from
highest score (top) to lowest (bottom).
doi:10.1371/journal.pone.0020585.t001
B. pertussis Vag8 Binds Human C1-Inhibitor
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20585probed with purified C1inh or serum, ruling out non-specific
binding of the antibodies to Vag8. Taken together, our data show
that the Vag8 passenger domain binds directly to human C1inh.
Serum sensitivity in the absence of Vag8 expression
We have previously shown that the ability of B. pertussis to bind
human C1inh is well-correlated with serum resistance [16]. By
using a serum killing assay, we aimed to confirm that expression of
Vag8 by B. pertussis, which we have shown to be essential for
binding human C1inh, is also crucial for serum resistance. We first
assayed BP338Vag8
2 and its parental strain BP338, as well as
BrkA mutant RFBP2152. As shown in figure 5A, mutant
BP338Vag8
2 exhibited similar serum sensitivity levels as the
BrkA mutant RFBP2152; both were significantly more sensitive to
serum-mediated killing than their parental wild type strain BP338.
We next looked at 18–323Sm
rVag8
2 and its parental strain 18–
323Sm
r. In comparison to its parental strain, 18–323Sm
rVag8
2
was also unable to bind C1inh and was significantly more serum
sensitive (Fig. 5B). Finally, we assessed serum resistance in the
BP338Vag8
2 strain complemented with pVag8. The partial
complementation of C1inh-binding exhibited in this strain was
not sufficient to restore serum resistance (not shown). In this
regard, it should be noted that whereas the BP338 and
BP338Vag8
2 strains grow similarly, the complemented strain
grows very slowly – likely due to the selection pressure imposed by
2 antibiotics, further complicating efforts to compare serum
resistance using this strain.
Discussion
Vag8 is a Bvg-activated 95-kDa autotransporter protein of
B. pertussis [25,27] whose function has remained elusive [28]. In the
present study we showed that disruption of vag8 abolishes binding
of C1inh and that complementing a Vag8 mutant with a plasmid
encoding a full-length vag8 ORF under control of the non-native
promoter Pcpn10 partially restores the C1inh-binding phenotype.
Furthermore, we demonstrated that purified Vag8 protein
(passenger domain) but not BrkA binds to C1inh in a dose-
dependent manner. These experiments clearly indicate that Vag8
is the C1inh binding factor. We also showed that disrupting vag8
(done two times independently in strain BP338, and once in 18–
323) significantly diminishes resistance to serum killing, linking the
phenotypes of C1inh binding and serum resistance to Vag8
expression. Taken together, our results show that expression of
Vag8 is essential for the ability of B. pertussis to bind human C1inh
during the virulent phase, and confers serum resistance.
Previously, a TnPhoA Vag8 mutant derived from B. pertussis
strain 18–323 was found to be slightly but not significantly more
serum sensitive than its parental strain which suggested a
negligible role of Vag8 in complement resistance [15]. However,
Figure 2. Generation of vag8 mutants and description of the vag8 genetic locus and predicted protein architecture. A Schematic of
the vag8 locus that is knocked out in B. pertussis mutant BP338Vag8
2. The 2748-bp coding sequence of vag8 is shown as an open arrow, with the
hatched region indicating the internal vag8 fragment which was cloned into vector pEG7 to generate vector pEG7-Vag8. Dashed lines indicate vector
sequence in the mutant strain. Solid lines indicate genomic sequence of BP338. vag8 is flanked by rRNA genes at the 59 end and locus tag BP2314 at
the 39 end (solid arrows, not drawn to scale). The bar indicates the 810-bp PCR product (shown in B) that was indicative of the correct genomic
integration of pEG7-Vag8 into the vag8 gene. C Architecture of the 95-kDaVag8 autotransporter protein. The predicted signal peptide and the
passenger and translocator domains are indicated. The region spanning residues 610 and 644 comprise a predicted alpha-helical linker region
present in all autotransporter proteins. Unlike many autotransporter proteins, Vag8 is not cleaved to separate its passenger domain from the
translocator. The duplicated fragments of vag8 in BP338Vag8
2 are missing sequences encoding the translocator and signal peptide respectively.
doi:10.1371/journal.pone.0020585.g002
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more serum sensitive in comparison to BP338 [15], whereas in the
present study, using a streptomycin-resistant derivative of 18–323,
we found the opposite. It is possible that low levels of serum
resistance of B. pertussis wild type strain 18–323 reported in the
previous study [15] were due to second site mutations in this
strain. Barnes and Weiss [29] have shown that growth phase
affects susceptibility to complement so it is also possible that the
Figure 3. A B. pertussis Vag8 mutant fails to bind C1inh. A Standard immunoblot analysis showing surface binding of the 104-kDa C1inh
protein to whole bacteria incubated in serum; B Far-Western analysis testing for the interaction of C1inh with a ca. 95- to 100-kDa factor of B.
pertussis. The left and right panels in A and B show the results with BP338Vag8
2 (vag8::pEG7-Vag8) and BP338BipA
2 (bipA::pTEN34), respectively. C
Immunoblot probed for the BvgAS-activated autotransporter protein BrkA. D Immunoblot analysis showing surface binding of C1inh to wild type B.
pertussis (BP338) and the BP338Vag8
2 mutant complemented with pVag8. BP338Vag8
2 complemented with control plasmids pBBR1MCS2 (empty
vector) or pBrkA (vector with the brkA gene under control of Pcpn10) did not bind C1inh.
doi:10.1371/journal.pone.0020585.g003
Figure 4. Purified histidine-tagged Vag8 passenger domain binds C1inh. Shown are means 6 SD of a representative ELISA done in
triplicate, where Nunc MaxiSorpH flat-bottom 96 well plates were coated with increasing two-fold concentrations of purified histidine-tagged Vag8
passenger or purified histidine-tagged BrkA passenger, and after blocking non-specific binding, incubated with either 10 mg/ml purified C1inh (A), or
2% normal human serum diluted in 16Veronal buffer (B). For each graph shown, two independent experiments were done.
doi:10.1371/journal.pone.0020585.g004
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may have been due to a growth-phase effect since the growth rates
of BP338 and 18–323 and its derivatives are different. Indeed, in
addition to growth phase, the absolute levels of serum resistance
can be affected by a number of parameters including strain origin,
the concentration of bacteria and serum used in the assay, time of
exposure to serum, and the labile nature of complement.
Nevertheless, despite the variability of the absolute levels of serum
resistance between experiments, the relative difference between
wild type and Vag8 mutants, in both BP338 and 18–323, was
always maintained and found to be approximately 10-fold.
Pathogens have evolved a number of mechanisms to evade the
complement system [30,31], including the ability to cleave
complement components or to bind complement regulatory
proteins that protect the host against unwanted damage. StcE is
a secreted metalloprotease from Escherichia coli O157:H7 that binds
to and cleaves C1inh, yet protects E. coli from complement-
dependent lysis [32]. StcE is proposed to bind the cell surface and
engage the heavily glycosylated amino terminus of C1inh. The
esterases C1r or C1s, which are involved in initiating the
complement cascade, are then inactivated by the cell-surface
bound C1inh. According to the model, it is after this step that StcE
cleaves C1inh to release the inactive C1inh-C1r/s complex
allowing it to become available for another round of the cycle.
This model has also been proposed for the Aeromonas hydrophila
ortholog TagA [33]. The mechanism by which Vag8 protects B.
pertussis is likely to be different. Vag8 shares no sequence identity
with StcE and it is not predicted to be a protease. Furthermore,
while it is not known how Vag8 engages C1inh, binding of C1inh
to B. pertussis requires its active serpin domain conformation but
not N-linked glycosylation [16] suggesting that how Vag8 interacts
with C1inh may also be different.
We have previously found that whereas phylogenetically distinct
strains of B. pertussis (Tohama I derivative BP338 and 18–323)
were capable of binding human C1inh, strains of other Bordetella
species, including B. bronchiseptica RB50 and NCTC 10540, B.
parapertussis 17903. B. holmesii ATCC 51541and B. avium Wba70
were not [16]. Accordingly, in contrast to B. pertussis Tohama I and
18–323, the Vag8 protein was found elsewhere [28] to be poorly
expressed in various B. bronchiseptica isolates and was undetectable
in whole-cell lysates from B. parapertussis isolates (upon growth
under similar conditions)—despite the presence of the Vag8
coding sequence in the genome of these Bordetella species. In the B.
avium genome, a vag8 gene is altogether absent [34]. A vag8
deletion mutant derived from B. pertussis 18–323 was found to
colonize mice as efficiently as the parental strain in a mouse
aerosol model of B. pertussis infection [28]. Thus, given these
observations, the role of Vag8-mediated binding of C1inh during
B. pertussis infection needs further study in order to fully elucidate
its role in B. pertussis pathogenesis. In this regard, it is interesting to
note that, in addition to the complement pathway, C1inh also
inhibits bradykinin formation. Bradykinin is a key mediator of
cough and it has been postulated that the sequestration of C1inh
by B. pertussis could result in its depletion in airways, leading to
coughing due to increased levels of bradykinin in the airways [35].
B. pertussis has a remarkable ability to bind human complement-
regulatory proteins. How this contributes to B. pertussis pathogen-
esis is under investigation in our laboratory.
Materials and Methods
Bacterial strains, plasmids and growth conditions
B. pertussis strains were grown at 37uC on Bordet-Gengou (BG)
agar (BD Biosciences) with 15% sheep blood (Dalynn) for 3 to 4
days. E. coli strains were cultured at 37uC in Luria-Bertani (LB)
broth or on LB agar. The following antibiotics were added to the
growth media: 30 mg/ml of nalidixic acid for B. pertussis wild type
strain BP338 and its mutants; 30 mg/ml of gentamicin for B.
pertussis mutants BP338BipA
2, BP338Vag8
2, 18–323Sm
rVag8
2,
RFBP2152, and BBC9BrkA; 100 mg/ml ampicillin for E. coli
Figure 5. Results of serum killing assays. A B. pertussis BP338 and its isogenic mutants, RFBP2152 (brkA::gent) and BP338Vag
2 (vag8::pEG7-
Vag8). Shown are means of percent survival 6 SEM of a representative experiment done in triplicate, *, P,0.04 vs. wild type strain. The comparison of
BP338 and BP338Vag8
2 was done 4 times independently, in triplicate; three of those experiments included RFBP2152. B B. pertussis 18–323Sm
r and
its isogenic mutant 18–323Sm
rVag8
2 (vag8::pEG7-Vag8). Shown are means of percent survival 6 SEM of a representative experiment done twice in
triplicate. *, P,0.004. Inset shows binding of C1inh (arrow) to wild type 18–323Sm
r but not to 18–323Sm
rVag8
2.
doi:10.1371/journal.pone.0020585.g005
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2
(Stratagene) and derivatives; 34 mg/ml of chloramphenicol for B.
pertussis or E. coli strains harboring pVag8 or pBrkA [16]); 50 mg/
ml of streptomycin for 18–323Sm
r and its isogenic mutant 18–
323Sm
rVag8
2;5 0 mg/ml of kanamycin for all B. pertussis
transposon mutants, and BBC9BrkA, and E. coli strains harboring
pBBR1MCS2 [36]. B. pertussis strains BP338, BP347and
BBC9BrkA and the transposon mutants have been described
previously [11,15,16]. The streptomycin-resistant 18–323 strain
(18–323-Sm
r) was isolated by plating 18–323 on streptomycin and
picking a resistant colony. The plasmids pEG7 [37] and pTEN34
[38] were a gift from Peggy Cotter (University of North Carolina).
Generation of B. pertussis Vag8 and BipA mutants
Suicide plasmid pTEN34 [38] was used to generate a BipA
mutant of strain BP338. To generate B. pertussis Vag8 knock-out
mutants, we constructed suicide vector pEG7-vag8 by PCR
amplification of an internal fragment of vag8 from genomic DNA
of strain BP338 or 18–323-Sm
r using primers BPvag8fw3
(CGCGGATCCCGTCCGAGCACGGTATCAACG) and BPva-
g8rev3 (GGAATTCCACATAGATCCCGGCGACTTCC), and
cloning of the PCR product into pEG7 [37] using BamHI and
EcoRI (New England Biolabs). Suicide vectors were introduced
into B. pertussis via conjugation using E. coli S17-1 as donor strain,
and B. pertussis mutants were selected by growth on BG agar
containing appropriate antibiotics (see above). Genomic integra-
tion of the suicide vectors into bipA or vag8 was verified by PCR
and sequencing of the generated products using pTEN34-specific
primer lacZrev1 (TCGCACTCCAGCCAGCTTTC) and BipAfw2
(GTGCTGGCCGCAAGTCGAG); or pEG7fw1 (TAGGCGTAT-
CACGAGGCCCTTTC) in combination with primer Vag8fw2
(CCCCAAGCTTCCAAGGCGTTTTCTGTCAATCG).
Complementation of vag8
vag8 was cloned downstream of the promoter region of B.
pertussis cpn10 in the pBBR1MCS vector backbone by swapping
out the brkA gene from pBrkA [16]. The detailed construction of
pBrkA [16]) is as follows. The entire brkA locus of vector pRF1066
[15], beginning from the NruI site of the adjacent brkB gene, was
cloned into the broad-range vector pBBR1MCS using NruI and
HindIII (New England Biolabs), and a 476-bp fragment of brkB
was deleted using AatII (New England Biolabs). The promoter
region of cpn10 (Pcpn10) was amplified by PCR from genomic DNA
of B. pertussis BP338 (isolated with DNeasyH tissue kit from
QIAGEN according to the manufacturer’s instructions) using
VentH DNA polymerase (New England Biolabs) and primers
Pcpn10fw1 (GTGTATCCCGGTACCTGAGCCCAGC) and
Pcpn10rev1 (GACGCAGGTACCTGAGGAACTCCTG). To
drive brkA expression, the PCR-amplified Pcpn10 sequence was
cloned into the vector construct described above by use of KpnI
(New England Biolabs). Correct Pcpn10 orientation was confirmed
by restriction digest with SmaI (New England Biolabs).
pVag8 was cloned as follows. The vag8 gene was amplified from
genomic DNA of BP338 using Platinum Pfx DNA polymerase
(Invitrogen) and primers BPvag8fw2 (CCCCAAGCTTCCAA-
GGCGTTTTCTGTCAATCG) and BPvag8rev2 (CGCTCTA-
GAGCATCGCCGTACCCTGAGC). Using the enzymes Hin-
dIII and XbaI (New England Biolabs), the amplified vag8 gene was
cloned into pBlueScript II KS
2 (Stratagene) to generate the vector
pBSvag8. pBrkA was digested with XhoI (New England Biolabs)
and XbaI in order to remove the brkA gene from the vector,
leaving the pBBRPcpn10 backbone. pBSvag8 was digested with XhoI
and XbaI and the released vag8 fragment was cloned into the
pBBRPcpn10 backbone producing the vector pVag8. The vag8 gene
in pVag8was sequenced and found to be identical to the Tohama-
1 annotated sequence except for one silent mutation at base pair
246 (C to T).
The plasmids pBBR1MCS2 (empty vector), pBrkA and pVag8
were introduced into BP338Vag8KO via conjugation [11] or
electroporation [39].
Expression and purification of a histidine-tagged Vag8
passenger domain
A 1.7 kb fragment of DNA encoding the predicted passenger
domain of Vag8 (residues Val
40 to Leu
610) was amplified by PCR
from chromosomal DNA from BP338 using primers BPvag8fw8
(AAGGATCCGGTCACGGCAGCGCAGCG) and BPvag8rev7
(CCCCAAGCTTACAACTCGTTGGTCCGC), digested with
BamHI and HindIII, and cloned into pET30b (Novagen). The
resultant plasmid, pET30bVag8pass, was sequence-verified and
transformed into BL21 (Novagen). A single transformant was
picked, grown to an OD600 of approximately 0.6 and induced with
isopropyl-B-D-thiogalactopyranoside (IPTG) at a final concentra-
tion of 1 mM. Expression of the Vag8 passenger was confirmed by
immunoblot using an anti-His tag antibody (Santa Cruz
Biotechnology). The histidine-tagged Vag8 passenger was purified
under denaturing conditions using Ni-NTA using the procedure
previously described to purify the BrkA passenger [26]. Urea was
removed by dilution in order to promote folding of Vag8, and
folding (acquisition of beta structure) was assessed by circular
dichroism spectroscopy as described [26] at the Laboratory for
Molecular Biophysics at the University of British Columbia.
C1inh binding assays and other immunoanalyses
Freshly grown bacteria were harvested in pre-warmed (37uC)
Stainer-Scholte (SS) broth without supplements [11]. To test the
ability of viable B. pertussis cells to recruit C1inh from human
serum, we employed a surface-binding assay that we developed
[16]. In brief, bacteria were exposed to normal human serum for
15 min at 37uC, placed on ice for 5 min, washed 3 times and
pelleted. Cell-associated C1inh was detected by immunoblot
following SDS-PAGE. C1inh binding was also detected by a
Far-Western or gel-overlay assay. Far-Western analysis was
carried out similar to the gel overlay technique described by
Gauthier and Finlay [24] with some modifications. Whole-cell
lysates from 200-mL aliquots of bacteria at an OD600 of 0.25, or
purified Vag8 or BrkA passenger domains were subject to 11%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) without prior serum incubation. Following SDS-PAGE,
separated proteins were transferred onto an Immobilon-P
membrane (Millipore) using 10 mM 3-(cyclohexylamino)-1-pro-
panesulfonic acid (Research Organics) as transfer buffer (pH 11.0).
Transfer was carried out at 30 V overnight or at 100 V for 1 h.
Blots were washed three times for 20 min each in a 50 mM Tris
buffer (pH 8.0) with 20% isopropanol, and then three times for
20 min each in 50 mM Tris buffer (pH 8.0). Subsequently, the
blots were incubated two times for 30 min each in a buffer with
6 M guanidine-HCl and 50 mM Tris (pH 8.0), and then
extensively washed for .18 h at 4uC in a pre-cooled wash buffer
containing 0.05% Tween 20 and 50 mM Tris buffer (pH 8.0),
with numerous changes of the wash buffer. Blots were then
blocked with a 5% (w/v) skim milk solution in Tris-buffered saline
with 0.1% Tween 20 (TBST) and overlaid with 1% normal human
serum diluted in Veronal buffer (BioWhittacker), both for 1 h at
room temperature. Subsequently, blots were washed six times for
5 min each in TBST, and probed with 1/10,000 dilutions of
polyclonal goat anti-C1inh primary antibody (Calbiochem) and a
1/50,000 dilution of a horseradish peroxidase (HRP)-conjugated
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Laboratories Inc.) as described [16,40].
Standard immunoblot analysis was also used to test for BrkA
expression in B. pertussis strains [16,40] using a 1/30,000 dilution
of a rabbit anti-rBrkA antiserum [41] and a 1/10,000 or 1/50,000
dilution of a HRP-conjugated goat anti-rabbit secondary antibody
(Cappel, ICN Biomedicals) [16,40]. Western Lightning chemilu-
minescence regent (Perkin Elmer) and X-OMAT blue autoradi-
ography film (Kodak) were used for HRP detection.
To test C1inh binding by using ELISA, two-fold serial dilutions
of purified, recombinant Vag8 or BrkA in PBS (pH 7.4) were
prepared, with the top concentration at 5 mg/ml protein. Protein
dilutions were used to coat Nunc MaxiSorpH flat-bottom 96 well
plates over night at 4uC. All further steps were performed at room
temperature. Plates were washed three times with PBS (pH 7.4)
containing 0.05% Tween-20 (PBST) and non-specific binding was
blocked by adding 50 ml1 6ELISA Diluent solution (eBioscience)
to each well, followed by a 1 hr incubation. Following three
washes with PBST, plates were incubated for 1 hr either with
10 mg/ml purified human C1inh (Advanced Research Technol-
ogies) in 16ELISA Diluent solution or 2% normal human serum
diluted in 16 Veronal buffer (BioWhittaker), as indicated. Plates
were washed three times with PBST, and probed for 1 hr each
with 2 mg/ml goat anti-C1inh antibody (Calbiochem) and 1 mg/
ml HRP-conjugated donkey anti-goat secondary antibody (Jackson
ImmunoResearch Laboratories Inc.) in 16 ELISA Diluent
solution. After five final washes, HRP activity was measured using
TMB substrate (eBioscience) and following a standard ELISA
protocol.
B. pertussis membrane enrichments and mass
spectrometry analysis
Bacteria were grown on BG agar, harvested into, and washed
twice with 10 mL of ice cold sucrose-Tris/HCl buffer (250 mM
sucrose, 10 mM Tris, pH 7.0). After addition of EDTA to a final
concentration of 1 mM and 1 tablet of Complete mini protease
inhibitor cocktail (Roche), the cells were lysed by freeze-thawing
using a dry-ice ethanol bath followed by pulsed sonication under
constant cooling. The suspensions were centrifuged at 2000 g for
10 min at 4uC to pellet unbroken cells, and the supernatants were
subject to ultracentrifugation at 100,000 g for 1 hour at 4uCt o
pellet the membrane fraction. Pellets were resuspended in 2.5 ml
sucrose-Tris/HCl buffer and proteins were precipitated with
trichloroacetic acid. Precipitated proteins washed with 1 ml ice-
cold acetone and finally resuspended in 2 ml of sample buffer (7 M
urea, 2 M thiourea, 4% w/v CHAPS, 0.5% v/v IPG buffer,
0.002% bromophenol blue, 18 mM dithiothreitol). The samples
(40 ml) were then subjected to 11% SDS-PAGE, the polyacryl-
amide gel stained with Coomassie, and protein bands migrating at
approximately 95 to 100 kDa were excised. Gel samples were
analyzed by tandem mass spectrometry (MS/MS) at the MSL/
LMB Proteomics Core Facility at the University of British
Columbia. In brief, samples were subjected to reduction/
alkylation with dithiothreitol/iodoacetamide followed by digestion
with trypsin. The resulting peptides were desalted and concen-
trated with STAGE tips [42] and analyzed using a Thermo
Electron LTQ-Orbitrap. Ions search of the obtained data against
the MSDB database was performed using Mascot.
Serum killing assays
Serum killing assays were performed as previously described
[16] with the modification that viable bacteria were exposed to
10% normal or heat-inactivated human serum for 15 min ( 37uC)
instead of 1 h using 96-well cell culture cluster (round bottom) po-
lypropylene plates (Corning). The serum samples used in this study
and elsewhere [17]were obtained from an adult [41], who had no
recollection of exposure to B. pertussis. The percent survival was
calculated by dividing the number of colony forming units (CFU)
obtained after exposure of the bacteria to normal serum by the
number of CFU obtained after exposure to heat-inactivated serum
and multiplying this by 100. Unless otherwise noted, the
experiments were done at least twice in triplicate. The Student’s
t test was used for statistical analysis.
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